All In Biotech

Drug Trial Radar · NCT02849860

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

A Phase 1b Open-Label Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-121 Lotion in Subjects With Acne Vulgaris Under Maximal Use Conditions

Last checked: Nov 19, 2026Latest source record: Dec 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Feb 2014

Primary completion

Sep 2016

Study completion Oct 2016

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Jul 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion.

Conditions

  • Acne

Interventions

  • IDP-121 LotionDrug

    Lotion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluators Global Severity Score at Day 15Time frame: 15 Days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Valeant Site 02

    Austin, Texas

  • Valeant Site 01

    College Station, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.